Evidence map›Paper›PMID 41601623›Full record

ArticleFrontiers in immunology2025

Integrated multi-omics and single-cell analysis identify SERPINE1 as a key mediator of the inflammatory tumor microenvironment in PDAC.

Di Wang, Qing Chen, Can-Ming Li, Yan Xie, Chunhui Yuan, Ren Lang, Wen-Tao Jiang

Abstract read
In one paragraph

Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Di Wang *Department of Liver Transplantation, First Central Hospital of Tianjin Medical University, Tianjin, China.
Qing Chen *Department of General Surgery, Peking University Third Hospital, Beijing, China.
Can-Ming Li *Department of Liver Transplantation, First Central Hospital of Tianjin Medical University, Tianjin, China.
Yan XieDepartment of Liver Transplantation, First Central Hospital of Tianjin Medical University, Tianjin, China.
Chunhui YuanDepartment of General Surgery, Peking University Third Hospital, Beijing, China.
Ren LangDepartment of Hepatobiliary and Pancreaticosplenic Surgery, Beijing Chaoyang Hospital, Capital Medical University, Beijing, China.
Wen-Tao JiangDepartment of Liver Transplantation, First Central Hospital of Tianjin Medical University, Tianjin, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Chronic inflammation is increasingly recognized as a fundamental driver of pancreatic ductal adenocarcinoma (PDAC) initiation and progression. Although numerous bioinformatics studies have characterized genetic alterations in PDAC, the key inflammatory regulators that bridge tumor cells and the immunosuppressive stroma remain unclear. Methods: We conducted an integrative multi-omics analysis of TCGA, GEO, and ArrayExpress datasets to define inflammation-associated molecular signatures in PDAC. Differentially expressed genes were analyzed through pathway enrichment, protein-protein interaction modeling, and immune infiltration profiling. Immunotherapeutic relevance was assessed using the IMvigor210 cohort and TIDE algorithm, while drug repurposing candidates were identified via molecular docking. Single-cell RNA sequencing and Results: Our multi-cohort analysis revealed a robust inflammation-associated gene network in PDAC, with SERPINE1 emerging as a consistent central hub. Elevated Conclusions: This integrative multi-omics and single-cell analysis establishes SERPINE1 as a central orchestrator of inflammation-driven stromal remodeling and immune evasion in PDAC. Its strong prognostic power, combined with newly revealed druggability, positions SERPINE1 as a tractable therapeutic axis for precision immunotherapy and rational drug repurposing. These findings provide a mechanistically grounded and clinically actionable entry point into targeting the inflammatory tumor microenvironment of pancreatic cancer.

Indexed as

Carcinoma, Pancreatic DuctalPancreatic NeoplasmsPlasminogen Activator Inhibitor 1Tumor MicroenvironmentCell Line, TumorGene Expression ProfilingGene Expression Regulation, NeoplasticHumansInflammationMolecular Docking SimulationMultiomicsSingle-Cell AnalysisPlasminogen Activator Inhibitor 1SERPINE1 protein, humaninflammatory tumor microenvironmentmulti-omicspancreatic ductal adenocarcinomaSERPINE1single-cell RNA sequencing

Identifiers

PMID41601623
PMCPMC12833254

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.